Item 5. Other Information
ITEM 5. OTHER
INFORMATION.
None.
32
ITEM 6. EXHIBITS
Filing
Filed
Number
Exhibit
Description
Form
Exhibit
Date
Herewith
10.01
Exclusive Option and Asset Purchase Agreement, by and between Enteris Biopharma, Inc., SWK Holdings Corporation and AptarGroup, Inc., dated March 13, 2024.
8-K
10.1
3/19/24
10.02†
Consulting Agreement, by and between SWK Holdings Corporation and Yvette Heinrichson, dated February 14, 2024.**
☒
31.01
Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
☒
32.01
Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
☒
101.INS+
XBRL
Instance
☒
101.SCH+
XBRL
Taxonomy Extension Schema
☒
101.CAL+
XBRL
Taxonomy Extension Calculation
☒
101.DEF+
XBRL
Taxonomy Extension Definition
☒
101.LAB+
XBRL
Taxonomy Extension Labels
☒
101.PRE+
XBRL
Taxonomy Extension Presentation
☒
* These
certifications accompany this Quarterly Report on Form 10-Q. They are not deemed “filed”
with the Securities and Exchange Commission and are not to be incorporated by reference in
any filing of SWK Holdings Corporation under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended, whether made before or after the date hereof
and irrespective of any general incorporation language in any filings.
** Management
contracts and compensatory plans and arrangements required to be filed as exhibits pursuant
to Item 15(b) of this report.
+ XBRL
information is furnished and not filed or a part of a registration statement or prospectus
for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and
otherwise is not subject to liability under these sections.
† Certain
portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation
S-K. The registrant agrees to furnish supplementally an unredacted copy of the exhibit to
the SEC upon request.
# Exhibits
and/or schedules to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation
S-K. The registrant agrees to furnish supplementally copies of any omitted exhibits or schedules
to the SEC upon request; provided, however, that the registrant may request confidential
treatment pursuant to Rule 24b-2 of the Exchange Act for any exhibits or schedules so furnished.
33
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized, on May 15, 2024.
SWK
Holdings Corporation
By:
/s/
Joe D. Staggs
Joe
D. Staggs
Chief
Executive Officer
(Principal
Executive Officer, Principal Financial and Accounting Officer)
34
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.